Jump to content

RU-28306

From Wikipedia, the free encyclopedia

RU-28306
Clinical data
Other namesRU28306; UCD0094; UCD-0094; 4,α-Methylene-N,N-dimethyltryptamine; 4,α-Methylene-DMT
Drug classSerotonin receptor agonist; Serotonin 5-HT1 and 5-HT2 receptor agonist; Dopamine D2 receptor agonist; Simplified/partial LSD analogue
ATC code
  • None
Identifiers
  • N,N-dimethyl-1,3,4,5-tetrahydrobenzo[cd]indol-4-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H16N2
Molar mass200.285 g·mol−1
3D model (JSmol)
  • c13c(C2)cccc1[nH]cc3CC2N(C)C
  • InChI=1S/C13H16N2/c1-15(2)11-6-9-4-3-5-12-13(9)10(7-11)8-14-12/h3-5,8,11,14H,6-7H2,1-2H3
  • Key:BQOANWOQEHVATQ-UHFFFAOYSA-N

RU-28306, also known as UCD0094 or as 4,α-methylene-N,N-dimethyltryptamine (4,α-methylene-DMT), is a non-selective serotonin receptor agonist as well as dopamine receptor agonist.[1][2][3] It is a cyclized tryptamine, specifically a conformationally restricted tricyclic derivative of dimethyltryptamine (DMT), and can also be considered a partial ergoline or simplified and deconstructed analogue of LSD.[1][2][3][4] However, unlike DMT and LSD, RU-28306 does not show psychedelic-like effects in animals.[1]

Pharmacology

[edit]

Pharmacodynamics

[edit]

RU-28306 shows affinity for the serotonin 5-HT1A receptor (Ki = 329 nM) and 5-HT2A receptor (Ki = 41–314 nM in different assays).[1][3][5][6] Its affinity for the serotonin 5-HT2A receptor was almost 2-fold higher than that of dimethyltryptamine (DMT) and 7-fold lower than that of LSD.[1][3][5][4] The drug acts as a potent partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[1][7] Its EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) values were 8.09 nM (52%) at the serotonin 5-HT2A receptor, 22.8 nM (33%) at the serotonin 5-HT2B receptor, and 11.1 nM (80%) at the serotonin 5-HT2C receptor.[1] RU-28306 showed 15-fold lower potency as a serotonin 5-HT2A receptor agonist and had about half the activational efficacy compared to LSD.[1]

In addition to its actions as a serotonin receptor modulator, RU-28306 has been found to show affinity for dopamine receptors and to act as a dopamine receptor agonist, including suppressing prolactin secretion in rodents.[2][8][9][10] Subsequently, in a more modern study, it was shown to act as a potent partial agonist specifically of the dopamine D2 receptor (EC50 = 29 nM; Emax = 78%).[1]

RU-28306 failed to produce the head-twitch, a behavioral proxy of psychedelic effects, in rodents.[1] This was in contrast to LSD, which robustly induces the response, and suggests that RU-28306 may lack hallucinogenic effects in humans.[1] Due to the fact that it activates the serotonin 5-HT2A receptor without producing the head-twitch response, RU-28306 has been proposed as a potential non-hallucinogenic psychoplastogen and attractive lead compound for other such agents.[1]

Chemistry

[edit]

Synthesis

[edit]

The chemical synthesis of RU-28306 has been described.[1] The synthesis requires 13 steps and has only 8% overall yield.[1] An asymmetric synthesis of RU-28306 to obtain its individual enantiomers has been published.[1]

Analogues

[edit]

RU-28306 shows far lower affinity for the serotonin 5-HT1A receptor than certain analogues like Bay R 1531 (LY-197206) and LY-178210 (LY-228729) (Ki = 329 nM and 0.67–1.3 nM, respectively).[11][6] Other analogues of RU-28306 include 6-MeO-RU-28306, RU-28251, RU-27849, and NDTDI, among others.

History

[edit]

RU-28306 was first described in the scientific literature by 1981.[8][9][3] It was encountered as a novel designer drug and was first reported to the EMCDDA by a forensic laboratory in Slovenia in 2017.[12] The drug was patented by David E. Olson and colleagues at Delix Therapeutics in 2021.[7] Subsequently, it was described in greater detail by Olson and colleagues in 2026.[1]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Basargin AG, Domokos A, Hennessey JJ, Aarrestad IK, Sambyal R, Khatib YA, et al. (September 2026). "Deconstruction of lysergic acid diethylamide". Proceedings of the National Academy of Sciences of the United States of America. 123 (38) e2603412123. doi:10.1073/pnas.2603412123. PMC 13598156. PMID 42709856.
  2. 1 2 3 Nichols DE, Billac GB, Harbit RC, Smith JM (November 2026). "A Pharmacological Basis for Some Bad LSD "Trips"?". Psychedelic Medicine 28314425261505140. New Rochelle, N.Y. doi:10.1177/28314425261505140. PMC 13768275. PMID 43034301.
  3. 1 2 3 4 5 Taylor EW, Nikam S, Weck B, Martin A, Nelson D (October 1987). "Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites". Life Sciences. 41 (16): 1961–1969. doi:10.1016/0024-3205(87)90749-1. PMID 3657392.
  4. 1 2 Nichols DE, Oberlender R, McKenna DJ (1991). "Stereochemical Aspects of Hallucinogenesis". In Watson RR (ed.). Biochemistry and Physiology of Substance Abuse. Vol. 3. Boca Raton, Fla.: CRC Press. pp. 1–39. ISBN 978-0-8493-4463-3. OCLC 26748320.
  5. 1 2 Taylor EW (1985). The Development of Indoleamine Derivatives Selective for Subtypes of Serotonin Receptors (Thesis). Retrieved 16 November 2026.
  6. 1 2 Nelson DL (December 1991). "Structure-activity relationships at 5-HT1A receptors: binding profiles and intrinsic activity". Pharmacology, Biochemistry, and Behavior. 40 (4): 1041–1051. doi:10.1016/0091-3057(91)90124-k. PMID 1816558.
  7. 1 2 WO 2021076572, Olson DU, Dunlap LU, Wagner FU, Chytil MU, Powell NU, Olson]] DE, Powell MC, "Ergoline-like compounds for promoting neural plasticity", published 22 April 2021, assigned to Delix Therapeutics, Inc. and The Regents of the University of California
  8. 1 2 Euvrard C, Ferland L, Fortin M, Oberlander C, Labrie F, Boissier JR (1981). "Dopaminergic activity of some simplified ergoline derivatives". Drug Development Research. 1 (2): 151–161. doi:10.1002/ddr.430010208. ISSN 0272-4391.
  9. 1 2 Boissier, J. R., & Dumont, C. (1983). New Simplified Central Nervous System Dopaminergic Ergoline Derivatives. Prolactin and Prolactinomas (pp. 115–126). New York: Raven Press. https://archive.org/details/prolactinprolact0000unse/page/115/mode/1up
  10. ↑ Kaiser C, Jain T (1985). "Dopamine receptors: functions, subtypes and emerging concepts". Medicinal Research Reviews. 5 (2): 145–229. doi:10.1002/med.2610050202. PMID 3887065.
  11. ↑ Glennon RA (1992). "Concepts for the design of 5‐HT 1A serotonin agonists and antagonists". Drug Development Research. 26 (3): 251–274. doi:10.1002/ddr.430260306. ISSN 0272-4391.
  12. ↑ "EMCDDA – Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). www.emcdda.europa.eu.
[edit]